Tumor necrosis factor-α: Life and death of hepatocytes during liver ischemia/reperfusion injury

Ochsner Journal

Volumn 13, Issue 1, 2013, Pages 119-130

  Shuh, Maureen ^a   Bohorquez, Humberto ^b,c   Loss, George E ^b,c   Cohen, Ari J ^a,b,c  

^a Institute of Translational Research   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Inflammation; Ischemia; Liver; Reperfusion; Tumor necrosis factor alpha

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NILOTINIB; SHORT HAIRPIN RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; ENTERITIS; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; KUPFFER CELL; LIVER CELL; LIVER ISCHEMIA; LIVER NECROSIS; LIVER TRANSPLANTATION; NATURAL KILLER CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PSORIASIS; PSORIATIC ARTHRITIS; REPERFUSION INJURY; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 84875128617     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (121)

1. Scientific Registry of Transplant Recipients. Liver, 2010 SRTR & OPTN Annual Data Report. http://srtr.transplant.hrsa.gov/ annual_reports/2010/flash/03_liver/index.html. Accessed November 1, 2012.
2. HRSA Health Resources and Services Administration. http:// optn.transplant.hrsa.gov/data/. Accessed September 13, 2012.
3. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984 Dec 20-1985 Jan 2;312(5996): 724-729.
4. Wang AM, Creasey AA, Ladner MB, et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science. 1985 Apr 12;228(4696):149-154.
5. Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature. 1985 Feb 28-Mar 6;313(6005):803-806.
6. National Institutes of Health. NCBI Reference Sequence. http:// www.ncbi.nlm.nih.gov/nuccore/NM_000594.3. Accessed November 1, 2012.
7. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997 Feb 20;385(6618):729-733.
8. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997 Feb 20;385(6618):733-736. Erratum in: Nature. 1997 Apr 17;386(6626):738.
9. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002 Oct 1;115(Pt 19):3719-3727.
10. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003 May 2;92(8):827-839.
11. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008 Oct;29(5):258-289. Epub 2008 Aug 15.
12. Jaiswal A, Chhabra A, Malhotra U, Kohli S, Rani V. Comparative analysis of human matrix metalloproteinases: Emerging therapeutic targets in diseases. Bioinformation. 2011 Mar 2; 6(1):23-30.
13. Parameswaran N, Patial S. Tumor necrosis factor-a signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20(2):87-103.
14. Hohmann HP, Remy R, Brockhaus M, van Loon AP. Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem. 1989 Sep 5; 264(25):14927-14934.
15. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem. 1993 Sep 5; 268(25):18542-18548.
16. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995 Dec 1;83(5): 793-802.
17. Schmid EF, Binder K, Grell M, Scheurich P, Pfizenmaier K. Both tumor necrosis factor receptors, TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtacrine tumor necrosis factor alpha. Blood. 1995 Sep 1; 86(5):1836-1841.
18. Vandenabeele P, Declercq W, Vanhaesebroeck B, Grooten J, Fiers W. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol. 1995 Mar 15; 154(6):2904-2913.
19. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptordeficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol. 1998 Jan 15;160(2):943-952.
20. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 1995 May 19;81(4):495-504.
21. Jiang Y, Woronicz JD, Liu W, Goeddel DV. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science. 1999 Jan 22;283(5401):543-546. Erratum in: Science. 1999 Mar 19;283(5409):1852.
22. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003 Jul 25;114(2):181-190.
23. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004 Jan 23;116(2):205-219.
24. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998 Aug 21;94(4):491-501.
25. Gross A, Yin XM, Wang K, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem. 1999 Jan 8;274(2):1156-1163.
26. Wei MC, Lindsten T, Mootha VK, et al. tBID, a membranetargeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 2000 Aug 15;14(16):2060-2071.
27. Li H, Kolluri SK, Gu J, et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science. 2000 Aug 18;289(5482):1159-1164.
28. Korsmeyer SJ, Wei MC, Saito M, et al. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ. 2000 Dec;7(12):1166-1173.
29. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001 Apr 27;292(5517):727-730.
30. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATPdependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997 Nov 14;91(4):479-489.
31. Jiang X, Wang X. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J Biol Chem. 2000 Oct 6;275(40):31199-31203.
32. Baliga B, Kumar S. Apaf-1/cytochrome c apoptosome: an essential initiator of caspase activation or just a sideshow? Cell Death Differ. 2003 Jan;10(1):16-18.
33. Ekert PG, Read SH, Silke J, et al. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factordeprived or drug-treated cells die. J Cell Biol. 2004 Jun 21; 165(6):835-842.
34. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998 Apr 15;17(8): 2215-2223.
35. Wilkinson JC, Cepero E, Boise LH, Duckett CS. Upstream regulatory role for XIAP in receptor-mediated apoptosis. Mol Cell Biol. 2004 Aug;24(16):7003-7014.
36. Slee EA, Harte MT, Kluck RM, et al. Ordering the cytochrome cinitiated caspase cascade: hierarchical activation of caspases-2,-3,-6,-7,-8, and-10 in a caspase-9-dependent manner. J Cell Biol. 1999 Jan 25;144(2):281-292.
37. Slee EA, Adrain C, Martin SJ. Executioner caspase-3,-6, and-7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem. 2001 Mar 9;276(10):7320-7326. Epub 2000 Oct 31.
38. Kroemer G, Galluzzi L, Vandenabeele P, et al; Nomenclature Committee on Cell Death 2009. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009 Jan;16(1):3-11. Epub 2008 Oct 10.
39. He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009 Jun 12;137(6):1100-1111.
40. Duprez L, Bertrand MJ, Vanden Berghe T, et al. Intermediate domain of receptor-interacting protein kinase 1 (RIPK1) determines switch between necroptosis and RIPK1 kinasedependent apoptosis. J Biol Chem. 2012 Apr 27;287(18): 14863-14872. Epub 2012 Feb 23.
41. Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009 Jun 12; 137(6):1112-1123.
42. Rosenbaum DM, Degterev A, David J, et al. Necroptosis, a novel form of caspase-independent cell death, contributes to neuronal damage in a retinal ischemia-reperfusion injury model. J Neurosci Res. 2010 May 15;88(7):1569-1576.
43. Linkermann A, De Zen F, Weinberg J, Kunzendorf U, Krautwald S. Programmed necrosis in acute kidney injury. Nephrol Dial Transplant. 2012 Sep;27(9):3412-3419.
44. Linkermann A, Bräsen JH, Himmerkus N, et al. Rip1 (receptorinteracting protein kinase 1) mediates necroptosis and contributes to renal ischemia/reperfusion injury. Kidney Int. 2012 Apr;81(8):751-761. Epub 2012 Jan 11.
45. Oerlemans MI, Koudstaal S, Chamuleau SA, et al. Targeting cell death in the reperfused heart: Pharmacological approaches for cardioprotection. Int J Cardiol. 2012 Mar 27. [Epub ahead of print].
46. Tang ZY, Loss G, Carmody I, Cohen AJ. TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats. Transplantation. 2006 Dec 15;82(11):1518-1523.
47. Zetzmann CP, Swamy OR, Loss GE Jr, Bohorquez H, Cohen AJ. Improving donor livers by inhibiting TNF-a production. Ochsner J. 2010 Winter;10(4):250-255.
48. Shuh M, Swamy OR, Zetzmann CP, et al. Tissue inhibitor of metalloproteinase-3 ameliorates total sublethal hepatic ischemia/reperfusion injury in a rat model. J Transplant Technol Res. 2012;S3-003.
49. Zhang SQ, Kovalenko A, Cantarella G, Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity. 2000 Mar;12(3):301-311.
50. Devin A, Cook A, Lin Y, et al. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity. 2000 Apr;12(4): 419-429.
51. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell. 2006 Apr 21;22(2): 245-257. Epub 2006 Apr 6.
52. Varfolomeev E, Goncharov T, Fedorova AV, et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem. 2008 Sep 5;283(36):24295-24299. Epub 2008 Jul 11.
53. Wang C, Deng L, Hong M, et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001 Jul 19;412(6844):346-351.
54. Hayden MS, Ghosh S. NF-jB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 2012 Feb 1;26(3):203-234.
55. Natoli G, Costanzo A, Ianni A, et al. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science. 1997 Jan 10;275(5297):200-203.
56. Baud V, Liu ZG, Bennett B, et al. Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an aminoterminal effector domain. Genes Dev. 1999 May 15;13(10): 1297-1308.
57. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-45.
58. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011 Mar;75(1):50-83. Erratum in: Microbiol Mol Biol Rev. 2012 Jun;76(2):496.
59. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NFkappaB signals induce the expression of c-FLIP. Mol Cell Biol. 2001 Aug;21(16):5299-5305.
60. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 1996 Jun 14;85(6):817-827.
61. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem. 1999 Jan 15;274(3):1541-1548.
62. Chang DW, Xing Z, Pan Y, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 2002 Jul 15;21(14):3704-3714.
63. Sprick MR, Rieser E, Stahl H, et al. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 2002 Sep 2;21(17): 4520-4530.
64. Boatright KM, Deis C, Denault JB, Sutherlin DP, Salvesen GS. Activation of caspases-8 and_10 by FLIP(L). Biochem J. 2004 Sep 1;382(Pt 2):651-657.
65. Fricker N, Beaudouin J, Richter P, et al. Model-based dissection of CD95 signaling dynamics reveals both a pro-and antiapoptotic role of c-FLIPL. J Cell Biol. 2010 Aug 9;190(3): 377-389.
66. Micheau O, Thome M, Schneider P, et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem. 2002 Nov 22;277(47):45162-45171. Epub 2002 Sep 4.
67. Peter ME. The flip side of FLIP. Biochem J. 2004 Sep 1;382(Pt 2):e1-e3.
68. Chang L, Kamata H, Solinas G, et al. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell. 2006 Feb 10;124(3):601-613.
69. Zhai Y, Shen XD, O'Connell R, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol. 2004 Dec 15;173(12):7115-7119.
70. Tsung A, Hoffman RA, Izuishi K, et al. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol. 2005 Dec 1;175(11):7661-7668.
71. Shen XD, Ke B, Zhai Y, et al. Absence of toll-like receptor 4 (TLR4) signaling in the donor organ reduces ischemia and reperfusion injury in a murine liver transplantation model. Liver Transpl. 2007 Oct;13(10):1435-1443.
72. Ellett JD, Evans ZP, Atkinson C, et al. Toll-like receptor 4 is a key mediator of murine steatotic liver warm ischemia/reperfusion injury. Liver Transpl. 2009 Sep;15(9):1101-1109.
73. Hisama N, Yamaguchi Y, Miyanari N, et al. Ischemia-reperfusion injury: the role of Kupffer cells in the production of cytokineinduced neutrophil chemoattractant, a member of the interleukin-8 family. Transplant Proc. 1995 Apr;27(2):1604-1606.
74. Hisama N, Yamaguchi Y, Ishiko T, et al. Kupffer cell production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion injury in rats. Hepatology. 1996 Nov; 24(5):1193-1198.
75. Wanner GA, Müller PE, Ertel W, et al. Differential effect of anti-TNF-alpha antibody on proinflammatory cytokine release by Kupffer cells following liver ischemia and reperfusion. Shock. 1999 Jun;11(6):391-395.
76. Nakamitsu A, Hiyama E, Imamura Y, Matsuura Y, Yokoyama T. Kupffer cell function in ischemic and nonischemic livers after hepatic partial ischemia/reperfusion. Surg Today. 2001;31(2): 140-148.
77. Mosher B, Dean R, Harkema J, et al. Inhibition of Kupffer cells reduced CXC chemokine production and liver injury. J Surg Res. 2001 Aug;99(2):201-210.
78. Zwacka RM, Zhang Y, Halldorson J, et al. CD4({thorn}) Tlymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J Clin Invest. 1997 Jul 15;100(2):279-289.
79. Colletti LM, Cortis A, Lukacs N, et al. Tumor necrosis factor upregulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock. 1998 Sep; 10(3):182-191.
80. Ke B, Shen XD, Gao F, et al. The CD154-CD40 T-cell costimulation pathway in liver ischemia and reperfusion inflammatory responses. Transplantation. 2005 May 15;79(9): 1078-1083.
81. Khandoga A, Kessler JS, Hanschen M, et al. Matrix metalloproteinase-9 promotes neutrophil and T cell recruitment and migration in the postischemic liver. J Leukoc Biol. 2006 Jun;79(6):1295-1305. Epub 2006 Mar 21.
82. Hanschen M, Zahler S, Krombach F, Khandoga A. Reciprocal activation between CD4{thorn}T cells and Kupffer cells during hepatic ischemia-reperfusion. Transplantation. 2008 Sep 15;86(5):710-718.
83. Kuboki S, Sakai N, Tschöp J, et al. Distinct contributions of CD4{thorn} T cell subsets in hepatic ischemia/reperfusion injury. Am J Physiol Gastrointest Liver Physiol. 2009 May;296(5):G1054-G1059. Epub 2009 Mar 5.
84. Kaudel CP, Frink M, van Griensven M, et al. FTY720 application following isolated warm liver ischemia improves long-term survival and organ protection in a mouse model. Transplant Proc. 2007 Mar;39(2):493-498.
85. Kaudel CP, Frink M, Schmiddem U, et al. FTY720 for treatment of ischemia-reperfusion injury following complete renal ischemia; impact on long-term survival and Tlymphocyte tissue infiltration. Transplant Proc. 2007 Mar; 39(2):499-502.
86. Parra C, Salas P, Dominguez J. Effects of immunosuppressive drugs on rat renal ischemia reperfusion injury. Transplant Proc. 2010 Jan-Feb;42(1):245-247.
87. Shen XD, Ke B, Zhai Y, et al. CD154-CD40 T-cell costimulation pathway is required in the mechanism of hepatic ischemia/reperfusion injury, and its blockade facilitates and depends on heme oxygenase-1 mediated cytoprotection. Transplantation. 2002 Aug 15;74(3):315-319.
88. Moore TM, Shirah WB, Khimenko PL, et al. Involvement of CD40-CD40L signaling in postischemic lung injury. Am J Physiol Lung Cell Mol Physiol. 2002 Dec;283(6):L1255-L1262. Epub 2002 Aug 9.
89. Ishikawa M, Vowinkel T, Stokes KY, et al. CD40/CD40 ligand signaling in mouse cerebral microvasculature after focal ischemia/reperfusion. Circulation. 2005 Apr 5;111(13):1690-1696. Epub 2005 Mar 28.
90. Khandoga A, Hanschen M, Kessler JS, Krombach F. CD4{thorn} T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets. Hepatology. 2006 Feb;43(2):306-315.
91. Esch JS, Jurk K, Knoefel WT, et al. Platelet activation and increased tissue factor expression on monocytes in reperfusion injury following orthotopic liver transplantation. Platelets. 2010; 21(5):348-359.
92. Bhogal RH, Weston CJ, Curbishley SM, Adams DH, Afford SC. Activation of CD40 with platelet derived CD154 promotes reactive oxygen species dependent death of human hepatocytes during hypoxia and reoxygenation. PLoS One. 2012;7(1): e30867. Epub 2012 Jan 25.
93. Lapchak PH, Ioannou A, Kannan L, et al. Platelet-associated CD40/CD154 mediates remote tissue damage after mesenteric ischemia/reperfusion injury. PLoS One. 2012;7(2):e32260. Epub 2012 Feb 27.
94. Shimamura K, Kawamura H, Nagura T, et al. Association of NKT cells and granulocytes with liver injury after reperfusion of the portal vein. Cell Immunol. 2005 Mar;234(1):31-38.
95. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med. 2006 Nov 27;203(12):2639-2648. Epub 2006 Nov 6.
96. Li L, Huang L, Sung SS, et al. NKT cell activation mediates neutrophil IFN-gamma production and renal ischemiareperfusion injury. J Immunol. 2007 May 1;178(9):5899-5911.
97. Cao Z, Yuan Y, Jeyabalan G, et al. Preactivation of NKT cells with alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G249-G258. Epub 2009 Jun 25.
98. Osman M, Russell J, Granger DN. Lymphocyte-derived interferon-gamma mediates ischemia-reperfusion-induced leukocyte and platelet adhesion in intestinal microcirculation. Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G659-G663. Epub 2008 Dec 31.
99. Ascon M, Ascon DB, Liu M, et al. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int. 2009 Mar;75(5):526-535. Epub 2008 Dec 17.
100. Shibamoto T, Tsutsumi M, Kuda Y, et al. Mast cells are not involved in the ischemia-reperfusion injury in perfused rat liver. J Surg Res. 2012 May 1;174(1):114-119. Epub 2010 Dec 18.
101. Yamada Y, Webber EM, Kirillova I, Peschon JJ, Fausto N. Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology. 1998 Oct;28(4):959-970.
102. Mohammed FF, Smookler DS, Taylor SE, et al. Abnormal TNF activity in Timp3-/-mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet. 2004 Sep;36(9): 969-977. Epub 2004 Aug 22.
103. Knight B, Yeoh GC. TNF/LTalpha double knockout mice display abnormal inflammatory and regenerative responses to acute and chronic liver injury. Cell Tissue Res. 2005 Jan;319(1):61-70. Epub 2004 Nov 3.
104. Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-a inhibitors. Expert Opin Drug Saf. 2012 Jan; 11(1):1-5. Epub 2011 Oct 20.
105. Kerensky TA, Gottlieb AB, Yaniv S, Au SC. Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf. 2012 Jan;11(1):121-139. Epub 2011 Nov 11.
106. Ben-Ari Z, Hochhauser E, Burstein I, et al. Role of anti-tumor necrosis factor-alpha in ischemia/reperfusion injury in isolated rat liver in a blood-free environment. Transplantation. 2002 Jun 27;73(12):1875-1880.
107. Mahmoud MF, El Shazly SM, Barakat W. Inhibition of TNF-a protects against hepatic ischemia-reperfusion injury in rats via NF-jB dependent pathway. Naunyn Schmiedebergs Arch Pharmacol. 2012 May;385(5):465-471. Epub 2012 Feb 8.
108. Hernandez-Alejandro R, Zhang X, Croome KP, et al. Reduction of liver ischemia reperfusion injury by silencing of TNF-a gene with shRNA. J Surg Res. 2012 Aug;176(2):614-620. Epub 2011 Nov 1.
109. Cain BS, Meldrum DR, Meng X, et al. p38 MAPK inhibition decreases TNF-alpha production and enhances postischemic human myocardial function. J Surg Res. 1999 May 1;83(1):7-12.
110. Mocanu MM, Baxter GF, Yue Y, Critz SD, Yellon DM. The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Res Cardiol. 2000 Dec;95(6):472-478.
111. Schneider S, Chen W, Hou J, Steenbergen C, Murphy E. Inhibition of p38 MAPK alpha/beta reduces ischemic injury and does not block protective effects of preconditioning. Am J Physiol Heart Circ Physiol. 2001 Feb;280(2):H499-H508.
112. Gao F, Yue TL, Shi DW, et al. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res. 2002 Feb 1;53(2):414-422.
113. Kaiser RA, Lyons JM, Duffy JY, et al. Inhibition of p38 reduces myocardial infarction injury in the mouse but not pig after ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2747-H2751. Epub 2005 Sep 2.
114. Jaswal JS, Gandhi M, Finegan BA, Dyck JR, Clanachan AS. Inhibition of p38 MAPK and AMPK restores adenosine-induced cardioprotection in hearts stressed by antecedent ischemia by altering glucose utilization. Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H1107-H1114. Epub 2007 May 11.
115. Gao F, Yan WL, Zhang HF, Shi DW, Mo QZ, Ma XL. [Antiapoptotic effect of insulin in myocardial ischemia-reperfusion and its principal signaling pathway]. Zhonghua Nei Ke Za Zhi. 2003 Mar;42(3):153-156. Chinese.
116. Bell JR, Eaton P, Shattock MJ. Role of p38-mitogen-activated protein kinase in ischaemic preconditioning in rat heart. Clin Exp Pharmacol Physiol. 2008 Feb;35(2):126-134. Epub 2007 Sep 24.
117. Bassi R, Heads R, Marber MS, Clark JE. Targeting p38-MAPK in the ischaemic heart: kill or cure? Curr Opin Pharmacol. 2008 Apr;8(2):141-146. Epub 2008 Mar 4.
118. Yoshinari D, Takeyoshi I, Kobayashi M, et al. Effects of a p38 mitogen-activated protein kinase inhibitor as an additive to University of Wisconsin solution on reperfusion injury in liver transplantation. Transplantation. 2001 Jul 15;72(1):22-27.
119. Kobayashi M, Takeyoshi I, Yoshinari D, Matsumoto K, Morishita Y. P38 mitogen-activated protein kinase inhibition attenuates ischemia-reperfusion injury of the rat liver. Surgery. 2002 Mar; 131(3):344-349.
120. Wang Y, Tian FZ, Tang LJ, Shi L, Zhang XQ. [The role of p38 MAPK pathway in ischemia-reperfusion injury of isolated liver]. Zhonghua Gan Zang Bing Za Zhi. 2003 Mar;11(3):170-172. Chinese.
121. Ocuin LM, Zeng S, Cavnar MJ, et al. Nilotinib protects the murine liver from ischemia/reperfusion injury. J Hepatol. 2012 Oct; 57(4):766-773. Epub 2012 May 26.